US · Healthcare · Biotechnology
Analysts rate Mesoblast Ltd a buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $37.00.
| Fund | Stake |
|---|---|
| Morgan Stanley - Brokerage Accounts | 0.55% |
| BlackRock Inc | 0.51% |
| Susquehanna International Group, LLP | 0.35% |
| The Goldman Sachs Group Inc | 0.31% |
| BNP Paribas Investment Partners SA | 0.20% |
| UBS Group AG | 0.15% |
| SRS Capital Advisors Inc | 0.13% |
| Bank of America Corp | 0.08% |
| Document | Date |
|---|---|
| Current report (6-K) · Q2 FY2027 HEADLINE NUMBERS • The document is a Form 6-K filing by Mesoblast Limited, dated October 16, 2026. • The filing states that Mesoblast submitted a ne | 2026-10-16 |
| Current report (6-K) · Q2 FY2027 HEADLINE NUMBERS • Mesoblast Limited filed a Form 6-K with the U.S. SEC for October 2026. • The filing was dated October 14, 2026, and relates to an | 2026-10-15 |
| Current report (6-K) · Q2 FY2027 HEADLINE NUMBERS • Mesoblast transitioned from a development-stage biotechnology company to a commercial-stage cellular-therapy company in fiscal 202 | 2026-10-13 |
| Current report (6-K) · Q1 FY2027 HEADLINE NUMBERS • The document only files Mesoblast Limited’s September 24, 2026 announcement with the U.S. Securities and Exchange Commission. • T | 2026-09-24 |
| Annual report FY2026 (20-F) HEADLINE NUMBERS • Mesoblast reported a net loss of $57.5 million for the year ended June 30, 2026. • Accumulated losses since inception were $1,068 | 2026-08-27 |
| Current report (6-K) · Q1 FY2027 HEADLINE NUMBERS • FY2026 net revenue was US$120.250M, up from US$17.198M in FY2025. • RYONCIL product sales were US$115.153M, compared with US$11.2 | 2026-08-27 |
| Current report (6-K) · Q1 FY2027 OTHER NOTABLE POINTS • Mesoblast Limited filed a Form 6-K with the U.S. Securities and Exchange Commission for August 2026. • On August 24, 2026, th | 2026-08-25 |
| Current report (6-K) · Q1 FY2027 HEADLINE NUMBERS • The document is a Form 6-K filing by Mesoblast Limited, covering an announcement filed with the Australian Securities Exchange on | 2026-08-24 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Split | 1 : 2 effective Jan 10, 2024 | 2024-01-10 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Mesoblast Ltd — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.